-
Findings from a new Australian study indicate that use of modern, low-dose oral contraceptives (OCs) containing 50 mcg estrogen or less do not appear to appreciably raise the risk of ischemic stroke in healthy women.
-
Just-published papers in the Journal of the American Medical Association add to heightened concern regarding hormone therapy (HT).
-
Women in the West African nation of Burkina Faso now have access to a lower-dose formulation of depot medroxyprogesterone acetate (DMPA) packaged in a novel injection system that is designed to increase access to contraception at all levels of the health system.
-
Research findings from the Contraceptive CHOICE Project, a St. Louis prospective cohort study, examined the short-term bleeding and cramping patterns of long-acting reversible contraception (LARC) methods and the impact on method satisfaction.
-
The North American Menopause Society and the International Society for the Study of Women’s Sexual Health have developed and endorsed the term “genitourinary syndrome of menopause” (GSM) to define “a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra and bladder.”
-
Research findings indicate that brief telephone counseling sustained long-term impact from a sexually transmitted infections/HIV intervention program among African American female adolescents.
-
Women in Texas face hurdles when it comes to getting long-acting reversible contraceptive (LARC) methods following cuts to the state family planning budget by the 2011 Texas State Legislature.
-
Your next patient in the clinic examination room is a 22-year-old who has just delivered her first child three weeks ago.
-
With Congress edging closer to enacting broad health care reform legislation, questions abound about its potential impact on patients and providers.
-
This issue marks the 30th anniversary of Contraceptive Technology Update.
